3-[(6,7-Dimethoxy-4-quinazolinyl)oxy]aniline → 1-(3-tert-butyl-1-(4-methylpyridin-3-yl)-1H-pyrazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea
Reaction equation
[C:1]([C:5]1[CH:9]=[C:8]([NH:10][C:11](=[O:13])[O-])[N:7]([C:14]2[CH:15]=[N:16][CH:17]=[CH:18][C:19]=2[CH3:20])[N:6]=1)([CH3:4])([CH3:3])[CH3:2].[CH3:21][O:22][C:23]1[CH:24]=[C:25]2[C:30](=[CH:31][C:32]=1[O:33][CH3:34])[N:29]=[CH:28][N:27]=[C:26]2[O:35][C:36]1[CH:37]=[C:38]([CH:40]=[CH:41][CH:42]=1)[NH2:39]>>[C:1]([C:5]1[CH:9]=[C:8]([NH:10][C:11]([NH:39][C:38]2[CH:40]=[CH:41][CH:42]=[C:36]([O:35][C:26]3[C:25]4[C:30](=[CH:31][C:32]([O:33][CH3:34])=[C:23]([O:22][CH3:21])[CH:24]=4)[N:29]=[CH:28][N:27]=3)[CH:37]=2)=[O:13])[N:7]([C:14]2[CH:15]=[N:16][CH:17]=[CH:18][C:19]=2[CH3:20])[N:6]=1)([CH3:2])([CH3:3])[CH3:4]Participants
3
Procedure
3-tert-Butyl-1-(4-methylpyridin-3-yl)-1H-pyrazol-5-ylcarbamate (105 mg, 0.30 mmol) was treated with 3-(6,7-dimethoxyquinazolin-4-yloxy)aniline (89 mg, 0.30 mmol) (prepared as described in Example 113A) using the procedure in Example 115C to give 1-(3-tert-butyl-1-(4-methylpyridin-3-yl)-1H-pyrazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea (145 mg, 0.26 mmol, 87%). 1H NMR (300 MHz, DMSO-d6) δ 9.02 (s, 1H), 8.58-8.51 (m, 3H), 8.38 (s, 1H), 7.54-7.47 (m, 3H), 7.38-7.32 (m, 2H), 7.12 (d, 1H), 6.91 (d, 1H), 6.36 (s, 1H), 3.98 (s, 6H), 2.06 (s, 3H), 1.24 (s, 9H); LC-MS (ESI) m/z 554 (M+H)+.
Sources & evidence
- ORD record
- ord-9d47f306822749669edb94c4f8deffbe
- Source dataset
- uspto-grants-2015_03
- Patent number
- US08969587B2
Reaction notes
Loading…